Home hemodialysis device designed to deliver more frequent or extended duration dialysis DEERFIELD, Ill., (December 20, 2013) - Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy. "Globally, less than 1 percent of the estimated 1.9 million patients requiring hemodialysis currently perform High Dose HD therapy," said Bruce Culleton, M.D., senior medical director, Baxter. "VIVIA will allow a greater number of hemodialysis patients access to High Dose HD therapy in their home environment."